Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF Vaccine in High-Risk Adults in Japan
NCT07543380Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2026
- Primary completion
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started May 2026; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07543380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07543380.